Syneos Health is collaborating with Elligo Health Research to help identify patients for clinical trials using electronic health records, as well as provide the infrastructure to allow those patients’ physicians to conduct the research in their own offices.
The collaboration may include deploying staff to provide training and the regulatory guidance necessary for running a clinical trial, with the goal of finding and enlisting trial participants that were previously inaccessible, the two companies said in a statement.
Syneos and Elligo hope the centrally managed approach will redefine the idea of a clinical trial site footprint—bringing research opportunities to underrepresented populations through community-based medical practices, in addition to reducing timelines and overall costs for the contract research organization.
“Our biopharma acceleration model is designed to completely surround the patient, caregiver or any stakeholder with the most relevant solutions to make the clinical trial process easier and more accessible,” said Alistair Macdonald, CEO of Raleigh, North Carolina-based Syneos, in a release. “Our collaboration with Elligo allows us to do just that. By leveraging data, technology and trusted physician relationships, we believe we can radically reduce enrollment times and impact health outcomes on behalf of our customers.”
RELATED: INC Research/inVentiv Health rebrands as Syneos Health
Last year, Austin, Texas-based Elligo signed on to a similar collaboration with health IT provider Allscripts. The project allows users of Allscripts’ EHR platforms to become study investigators through Elligo’s services, granting access to 45,000 research-capable physician practices.
RELATED: Elligo to test FDA’s real-world data model for immunotherapy safety assessment
In March, Elligo raised $16 million in venture capital financing to expand its work.
“Our programs speak specifically to the medical practices that are hesitant to perform research in their offices due to lack of resources and infrastructure,” Elligo CEO John Potthoff, Ph.D., said after the series B round. “The new funding will help us expand our services and not only make research studies more accessible to physician sites but also streamline data collection and submission processes.”